<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the effect of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> on progressive inner hair cell (IHC) loss following transient cochlear <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in gerbils </plain></SENT>
<SENT sid="1" pm="."><plain>Transient cochlear <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by 15-min bilateral vertebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>An alpha-amino-3-hydroxy-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-<z:chebi fb="0" ids="35595">isoxazole</z:chebi> <z:chebi fb="0" ids="30768">propionic acid</z:chebi> (AMPA)/kainate-type <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, 6-7-dinitroquinoxaline-2,3-dione (DNQX), or an <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>)-type receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, MK-801, was administered 10 min before the ischemic insult </plain></SENT>
<SENT sid="3" pm="."><plain>Hearing was assessed by sequentially recording compound action potentials (CAPs) before, during, and after the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The degree of hair cell loss in the organ of Corti was evaluated in specimens stained with rhodamine-<z:chebi fb="0" ids="8040">phalloidin</z:chebi> and Hoechst 33342 </plain></SENT>
<SENT sid="5" pm="."><plain>On the seventh day after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, the increases in the CAP threshold and the progressive IHC loss were significantly reduced in cochleae treated with DNQX, while MK-801 was ineffective </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that the AMPA receptor plays a critical role in the development of the progressive IHC loss induced by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury in the cochlea </plain></SENT>
</text></document>